Editorial commentary: "Late" treatment with neuraminidase inhibitors for severely ill patients with influenza: Better late than never?

Nelson Lee*, Michael G. Ison

*Corresponding author for this work

Research output: Contribution to journalComment/debatepeer-review

12 Scopus citations
Original languageEnglish (US)
Pages (from-to)1205-1208
Number of pages4
JournalClinical Infectious Diseases
Volume55
Issue number9
DOIs
StatePublished - Nov 1 2012

Funding

ceived grant support from F. Hoffmann–La Roche for principal investigator–initiated clinical influenza research, paid to the Chinese University of Hong Kong; an honorarium for consultancy work for GlaxoSmithKline; and conference support from Sanofi-Aventis Hong Kong, MSD (Asia) and Pfizer Hong Kong, paid to the Chinese University of Hong Kong. M. G. I. has received research support, paid to Northwestern University Feinberg School of Medicine, from BioCryst, Cellex, Genentech/Roche, and Glaxo-SmithKline. He is a paid member of a data and safety monitoring board for NexBio and has provided remunerated consultation to Abbott, Crucell, and Genentech/Roche; he has also provided unremunerated consultation to Adamas, Alios, BioCryst, Biota, Cellex, Clarassance, Glaxo-SmithKline, MediVector/Toyama, TheraClone, and Visterra.

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this